Molecular targets such as FGFR2 fusion, IDH1/2 mutation, HER2 amplification and NTRK fusion are expected to be used for the targeted treatment of ICC, but most of them are currently in the phase clinical research [81]. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.